Onwards and upwards
Now that all the resolutions for Destiny’s fundraising that needed shareholder approval have been passed at its general meeting, we have taken the opportunity to update both our valuation and financials. Our valuation of the business increases marginally because, while we had lower milestone payment and royalty totals, they are partly offset by a launch a year later than we originally forecast.Our financials now reflect the milestone payment received, the cash raised and the higher share count. We have also extended out our forecasts for Destiny to YE 2024 since the company has stated that the Sebela transaction and the fundraising extends their cash runway until late 2024.
The Sebela deal and fundraising puts Destiny into a position of strength for the subsequent deals. Whilst not publishing forecasts beyond 2024, it is possible that with the flow of milestones and royalties from both licensing transactions, Destiny as it stands today may not need to come back to the markets again.
Our fair value for Destiny Pharma plc has increased modestly to £251.9m (or 267 pence per share) from £251.2m (or 345p per share), with the higher share count leading to the per share change.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.